Why Is Age-Related Blindness Focused EyePoint Pharmaceuticals Stock Trading Over 300% Today?

Zinger Key Points
  • The company says EYP-1901 achieved statistical non-inferiority to the aflibercept control.
  • Positive safety profile continues with no EYP-1901-related ocular or systemic SAEs was observed.

EyePoint Pharmaceuticals Inc EYPT announced topline results of its Phase 2 DAVIO 2 trial of EYP-1901, an investigational sustained delivery maintenance treatment for wet age-related macular degeneration (wet AMD) combining vorolanib, a selective tyrosine kinase inhibitor with bioerodible Durasert E

The clinical trial met its primary endpoint with both EYP-1901 doses (2mg and 3mg) demonstrating a statistical non-inferiority change in best corrected visual acuity (BCVA) compared to aflibercept control and a favorable safety profile with no EYP-1901-related ocular or systemic serious adverse events (SAEs). 

The 2mg and 3mg doses were only -0.3 and -0.4 letters different, respectively, versus on-label aflibercept. The lower limit of the non-inferiority margin is defined as -4.5 letters by the FDA, with five letters representing one line on the eye chart.

The trial also achieved key secondary endpoints with both EYP-1901 doses, including an over 80% reduction in treatment burden, nearly two-thirds of eyes supplement-free up to six months, and over 80% receiving only zero or one supplement up to six months. 

65% and 64% of eyes were supplement free up to six-months, respectively, for the 2mg and 3mg doses of EYP-1901.

Additionally, there was strong anatomical control with both EYP-1901 cohorts as measured by optical coherence tomography (OCT).

Patient discontinuation up to week 32 was low at 4%.

The company remains on track to initiate the Phase 2 VERONA trial in diabetic macular edema, anticipated in Q1 of 2024, and the readout of topline data from the Phase 2 PAVIA trial in non-proliferative diabetic retinopathy, expected in Q2 of 2024.

Price Action: EYPT shares are up 288.8% at $25.71 during the premarket session on the last check Monday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!